Dr Lizzie Mills

Polypharmacy is now part of everyday healthcare — but it carries risks, from drug interactions to reduced quality of life. In our podcast series Safe Prescribing: Navigating CYP3A and Polypharmacy, we explore how prescribers can make safer choices, drawing on expert insights, patient stories, and the latest developments in pharmacogenomics and AI.

The NHS is entering a new chapter—one shaped by artificial intelligence (AI), automation, and data-driven care. From streamlining clinical workflows to supporting earlier diagnoses, AI in the NHS has the potential to ease pressure on services, enhance patient outcomes, and free up time for what matters most: human connection in care.  But for this future to become a reality, one critical piece must be in place:  👉 a confident, capable healthcare workforce that understands how to use AI safely

Pancreatic cancer is often referred to as a “silent killer”—and for good reason. Its symptoms are vague, its onset subtle, and its detection notoriously difficult. Tragically, this means that most people are diagnosed too late, when treatment options are limited and outcomes are poor.  But one group of healthcare professionals may hold the key to earlier detection: community pharmacists.